-Reuters
Canaccord Genuity Maintains Buy on Cortexyme, Raises Price Target to $150
Canaccord Genuity analyst Sumant Kulkarni maintains Cortexyme (NASDAQ:CRTX) with a Buy and raises the price target from $75 to $150.
Fed’s Kashkari Says Factors Holding Back Labor Supply Should Be Better By September
-Reuters
Related Posts
Watching Sports Betting Stocks; Traders Circulate Late-Monday Report ‘FLORIDA SPORTS BETTING DEAD FOR NOW AFTER FEDERAL COURT RULING’
https://www.legalsportsreport.com/59846/florida-sports-betting-dead-after-court-ruling/
Jefferies Initiates Coverage On Rent the Runway with Buy Rating, Announces Price Target of $13
Jefferies initiates coverage on Rent the Runway (NASDAQ:RENT) with a Buy rating and announces Price Target of $13.
Pingtan Marine Enterprise Receives Extension From Nasdaq To Meet Bid Price Requirement
Pingtan Marine Enterprise Ltd. (NASDAQ:PME), ("Pingtan," or the "Company"), a fishing company based in the People's Republic of China, today announced that it received a notification from the